Lundbeck to Showcase New Findings at ENDO 2026: Focus on Neuroendocrine Therapies

Lundbeck to Present at ENDO 2026

Lundbeck, a prominent biopharmaceutical company recognized for its commitment to brain health, is set to unveil significant findings related to their neuroendocrine and neuroimmunology programs at the upcoming Endocrine Society's Annual Meeting (ENDO 2026), scheduled from June 13–16, 2026, in Chicago, Illinois. This year's presentations are centered around the company’s Focused Innovator strategy, which highlights its ongoing dedication to addressing rare neuroendocrine diseases that are often characterized as having high unmet medical needs.

Among the key presentations, Lundbeck will introduce preliminary Phase II data for asedebart, a monoclonal antibody targeting anti-adrenocorticotropic hormone (ACTH), which is currently being evaluated for the treatment of Cushing's Disease (CD). The data demonstrates Lundbeck’s innovative biomarker-supported approach that underpins novel therapeutic strategies for rare endocrine disorders. Cushing's Disease, a serious ailment primarily caused by ACTH-secreting pituitary adenomas, leads to excessive cortisol production and can result in substantial physical and psychological challenges for patients. Through careful dose titration of asedebart, the early findings suggest promising impacts on urinary free cortisol (UFC) levels, showcasing its potential therapeutic benefit.

Lundbeck also plans to present preclinical and exploratory findings from their research on Lu AG22515, a CD40L blocker intended for patients with thyroid eye disease (TED). TED is characterized by eye-related complications stemming from autoimmune disorders, many of which result in debilitating symptoms like proptosis and vision impairment. The insights from this exploratory research will shed light on how modulation of the CD40L pathway can influence disease biology and could lead to novel treatment avenues not only in TED but potentially across other immune-mediated conditions as well.

During the event, Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck, emphasized the importance of expanding the company's neuroscience heritage. He stated, "Lundbeck’s presence at ENDO 2026 signifies our sustained effort at developing targeted therapies that possess the potential to offer significant benefits in areas of acute medical need in neuroendocrinology. We are buoyed by the progress our innovative programs have made and are eager to present our findings to the scientific community."

The presentations scheduled at ENDO include an oral presentation detailing the Phase II trial of asedebart, which will discuss safety, tolerability, and pharmacokinetics in adults. Additionally, Lundbeck will cover the results of a Phase Ib trial evaluating Lu AG22515 concerning its implications on B-cell activation and its overall effectiveness in clinical settings.

The data generated from Lundbeck's studies will not only further clinical understanding of Cushing's Disease but establish groundwork for exploring autoimmune conditions as seen in TED. These findings have the potential to stimulate further inquiry into CD40L modulation in relevance to multiple aspects of neuroinflammatory ailments experienced in various neurological and endocrine contexts.

About Lundbeck

Lundbeck has been at the forefront of brain health research for over 70 years, focusing on enhancing the lives of individuals suffering from neurological and psychiatric disorders. Their mission is to build on existing knowledge to pioneer better treatment methods for complex brain conditions, especially those devoid of sufficient therapeutic options. Demonstrating commitment to neuroscience, Lundbeck seeks to efficiently drive innovation in the development of transformative therapies targeted for patients who are often left without effective treatments. Through strategic research alliances and a focused portfolio, Lundbeck aims to make a positive impact on lives worldwide, transcending borders to ensure healthcare equity and accessibility.

Expect to see more exciting advancements and discussions on neuroendocrine conditions at ENDO 2026, as Lundbeck shares its latest contributions to this vital area of biomedical research. The ongoing commitment to address hard-to-treat health issues remains a cornerstone of Lundbeck's operations, and their presentations at ENDO will undoubtedly contribute to advancements in therapeutic strategies.